A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Summary

The main purpose of this study is to learn more about the safety of LY3361237 and any side effects that might be associated with it when given to participants with systemic lupus erythematosis (SLE). LY3361237 will be administered by injections just under the skin. The study will last up to 26 weeks and may include up to 17 visits to the study center.

Timeline

Start

2019-05-21

Primary completion

2021-02-15

Completion

2021-02-15

Drugs

Indications